SCHEMBL25265262

SCHEMBL25265262

CN(C)c1ccc(C=CC(=O)c2ccc(N3CC(O)C3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 2/20 0.61
CRHBP P24387 1/20 0.61
CRHR2 Q13324 1/20 0.61
MAPT P10636 5/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
KMT2A Q03164 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
CASP3 P42574 1/20 0.59
CYP1B1 Q16678 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
MAOB P27338 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.52
CTSL P07711 2/20 0.51
CTSB P07858 2/20 0.51
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25198144 1.00 TLR9 (0.61) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL2911445 0.82 TLR9 (0.87) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL2911444 0.82 TLR9 (0.87) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL25205299 0.77 MAPT (0.79) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL5950048 0.77 MAPT (0.77) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL482965 0.77 MAPT (0.77) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL25185026 0.77 CRHBP (1.00) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL25200423 0.77 CRHBP (1.00) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL5950050 0.77 MAPT (0.77) TLR9CRHBPCRHR2MAPTNPC1
SCHEMBL25190978 0.77 MAPT (0.79) TLR9CRHBPCRHR2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 TLR9 4548/4885CRHBP 1079/4885CRHR2 3714/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 TLR9 4548/4885CRHBP 1079/4885CRHR2 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.